Under the five-year agreement extension, Quest will continue to provide broad access to Clinical Genomics's InSure One fecal immunochemical test in the US.
The firm plans to conduct a prospective trial of a pan cancer assay and aims to bring another assay focused on colorectal cancer through FDA clearance.
The measures are part of a long-term plan for the National Health Service that will be rolled out across the country to detect 3 out of every 4 cancers at an early stage.
While almost 57,000 labs received Medicare payments for labs performed last year, just three labs received 15 percent of the total Medicare lab payments.
MRM will develop immuno-MALDI mass spec assays to key cancer signaling proteins and test them in 100 breast and colorectal cancer samples provided by Exactis.
The test will be based on MRM Proteomics' immunoMALDI approach, which uses antibody enrichment of target proteins followed by analysis via MALDI mass spec.
Excluding the impact of the one-time sale of patents last year, the company's revenues climbed 38 percent on strong product and service revenue growth.
